A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD

Status:
Completed

Trial end date:
2020-03-31

Target enrollment:

Participant gender:

This study will assess the pharmacokinetics of PXL770 after 4 weeks of treatment.

Phase 1

Poxel SA